Almirall licenses an anti-il-21 monoclonal antibody from novo nordisk to develop it as a first-in-class agent in dermatology

Barcelona, spain--(business wire)--almirall s.a. (bme: alm), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with novo nordisk for rights to the il-21 blocking monoclonal antibody nn-8828. under the agreement, almirall obtains global rights to develop and commercialize this monoclonal antibody in certain fields, including immune inflammatory dermatological diseases. almirall will accelerate the development.
NVO Ratings Summary
NVO Quant Ranking